ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cytarabine

Also written as “cytarabine”, “Liposomal Annamycin Injection in combination with Cytarabine Injection” and “Cytarabine (Ara-C)”.

Its studies are mostly in Leukemia, Myeloid, Acute · Leukemia · Lymphoma · Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Mesothelioma, Malignant, led by 23 companies.

Drug pageCytarabine: every studyMany companies study it; this page follows only the 32 they lead. All 497 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 4, 200032 company-led studies, 5 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only30 open or runningphase 3since Oct 4, 2000Oct 4, 2000none ahead
Vion Pharmaceuticalsits history only30 open or runningphase 2since Jul 19, 2006Jul 8, 2003none ahead
Antisoma Researchits history only20 open or runningphase 3since Jul 14, 2008Jul 14, 2008none ahead
Boehringer Ingelheimits history only20 open or runningphase 2since Mar 4, 2008Mar 4, 2008none ahead
Hoffmann-La Rocheits history only20 open or runningphase 2since Aug 16, 2007Aug 16, 2007none ahead
Moleculin Biotechits history only21 open or runningphase 3since Dec 5, 2024Feb 22, 2022Aug 2029phase 3 · NCT06788756
Theradexits history only20 open or runningphase 2since Oct 3, 2003Jan 27, 2003none ahead
AbbVieits history only10 open or runningphase 3since Aug 10, 2020Aug 10, 2020none ahead
Arog Pharmaceuticalsits history only10 open or runningphase 2since Oct 18, 2017Oct 18, 2017none ahead
Cornerstone Pharmaceuticalsits history only10 open or runningphase 3since Apr 12, 2018Apr 12, 2018none ahead

Also a collaborator on its studies: Baili-Bio (Chengdu) Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Oct 4, 2000.

  1. Aug 9, 2016Polaris Group’s first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Polaris GroupPolaris Group · NCT02875093 · 23 enrolled · Taiwan
  2. Sep 27, 2017Sumitomo Pharma’s first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Sumitomo PharmaSumitomo Pharma · NCT03298984 · 32 enrolled · United States
  3. Oct 18, 2017Arog Pharmaceuticals’ first study: phase 2 study in RecurrenceNew to Arog PharmaceuticalsArog Pharmaceuticals · NCT03324243
  4. Dec 21, 2017Pfizer’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to PfizerPfizer · NCT03416179 · 730 enrolled · United States, Australia, Austria and more
  5. Apr 12, 2018Cornerstone Pharmaceuticals’ first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Cornerstone PharmaceuticalsCornerstone Pharmaceuticals · NCT03504410 · 200 enrolled · United States, Australia, Austria and more
  6. Aug 10, 2020AbbVie’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT04509622 · 14 enrolled · Japan
  7. Aug 19, 2020Oncovir’s first study: phase 1 study in Mesothelioma, MalignantNew to OncovirOncovir · NCT04525859 · 19 enrolled · United States
  8. Oct 19, 2021CSPC Pharmaceutical Group’s first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT05100303 · 58 enrolled · China
  9. Jan 16, 2022Tarapeutics Science’s first study: phase 2 study in RecurrenceNew to Tarapeutics ScienceTarapeutics Science · NCT05241093 · 18 planned · China
  10. Feb 22, 2022Moleculin Biotech’s first study: phase 2 study in Leukemia, Myeloid, AcuteNew to Moleculin BiotechMoleculin Biotech · NCT05319587 · 22 enrolled · Italy, Poland
  11. Jul 24, 2024Stelexis BioSciences’ first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Stelexis BioSciencesStelexis BioSciences · NCT06533761 · 105 planned · United States, Spain
  12. Dec 5, 2024Phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756 · 312 planned · United States, Czechia, Georgia and more
  13. May 16, 2025Kura Oncology’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Kura OncologyKura Oncology · NCT07007312 · 1,300 planned · United States, Australia, Belgium and more
  14. Nov 20, 2025Sichuan Biokin Pharmaceutical’s first study: phase 3 study in Leukemia, Myeloid, AcuteNew to Sichuan Biokin PharmaceuticalSichuan Biokin Pharmaceutical · NCT07255872 · 216 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Leukemia, Myeloid, AcuteSichuan Biokin Pharmaceutical · NCT07255872
  2. Dec 15, 2027Primary completion: phase 1 study in Leukemia, Myeloid, AcuteStelexis BioSciences · NCT06533761
  3. Aug 2029Primary completion: phase 3 study in Leukemia, Myeloid, AcuteMoleculin Biotech · NCT06788756
  4. Nov 2031Primary completion: phase 3 study in Leukemia, Myeloid, AcuteKura Oncology · NCT07007312

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 32 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07255872Leukemia, Myeloid, Acute · China3RecruitingSichuan Biokin PharmaceuticalDec 2027216
NCT07007312Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3RecruitingKura OncologyNov 20311,300
NCT06788756Leukemia, Myeloid, Acute · United States, Czechia, Georgia and more3RecruitingMoleculin BiotechAug 2029312
NCT06533761Leukemia, Myeloid, Acute · United States, Spain1RecruitingStelexis BioSciencesDec 15, 2027105
NCT05319587Leukemia, Myeloid, Acute · Italy, Poland2CompletedMoleculin BiotechAug 2, 202322
NCT05241093Recurrence · China2RecruitingTarapeutics ScienceDec 30, 202518
NCT05100303Recurrence · China2UNKNOWNCSPC Pharmaceutical GroupNov 202258
NCT04525859Mesothelioma, Malignant · United States1CompletedOncovirJun 18, 202519
NCT04509622Leukemia, Myeloid, Acute · Japan3CompletedAbbVieApr 15, 202114
NCT03504410Leukemia, Myeloid, Acute · United States, Australia, Austria and more3TerminatedCornerstone PharmaceuticalsOct 25, 2021200
NCT03416179Leukemia, Myeloid, Acute · United States, Australia, Austria and more3CompletedPfizerJun 5, 2020730
NCT03324243Recurrence2WithdrawnArog PharmaceuticalsDec 20200
NCT03298984Leukemia, Myeloid, Acute · United States1CompletedSumitomo PharmaMar 20, 202032
NCT02875093Leukemia, Myeloid, Acute · Taiwan1TerminatedPolaris GroupJul 10, 201923
NCT01773408Leukemia, Myeloid, Acute · United States, Australia, Canada and more1CompletedHoffmann-La RocheJun 2016122
NCT01500161Leukemia, Myeloid, Acute · United States2TerminatedTexas Oncology Cancer CenterNov 20131
NCT01066494Leukemia, Myeloid, Acute · Georgia, Ukraine2UNKNOWNAntisoma ResearchSep 201020
NCT00804856Leukemia, Myeloid, Acute · Austria, Belgium, Canada and more2CompletedBoehringer IngelheimMar 9, 2012180
NCT00715637Leukemia · United States, Argentina, Australia and more3UNKNOWNAntisoma ResearchJun 2010420
NCT00632749Leukemia, Myeloid, Acute · Germany2CompletedBoehringer IngelheimMar 201468
NCT00517699Lymphoma · Canada2TerminatedHoffmann-La RocheMar 20095
NCT00354276Leukemia · United States, France, United Kingdom2UNKNOWNVion PharmaceuticalsDec 200885
NCT00333840Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more3CompletedNovartisMar 20121,106
NCT00273884Leukemia, Myeloid, Acute · United States, Canada2CompletedXanthus Pharmaceuticals80
NCT00129168Leukemia, Myeloid2CompletedKanisa PharmaceuticalsMar 2008100
NCT00093600Leukemia, Myeloid, Acute · United States, Germany1CompletedNovartisJun 201169
NCT00074737Leukemia, Myeloid, Acute · United States2CompletedEleosMay 200753
NCT00070538Leukemia · United States1CompletedVion PharmaceuticalsSep 2004
NCT00069966Lymphoma · United States, Puerto Rico2UNKNOWNTheradex
NCT00064090Leukemia · United States1CompletedVion PharmaceuticalsSep 2004
NCT00053105Lymphoma · United States1UNKNOWNTheradex
NCT00006343Leukemia · United States3CompletedNovartisMar 2007

How it is read

Names in the registry

  • “Cytarabine”, 15 entries
  • “cytarabine”, 8 entries
  • “Liposomal Annamycin Injection in combination with Cytarabine Injection”, 2 entries
  • “Cytarabine (Ara-C)”, 1 entry
  • “Eganelisib in combination with cytarabine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.